Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 2 pages · Chinese
Release
Zhejiang Huakang Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Huakang Pharmaceutical
- Announcement on Cancellation of Some Proposals for the 2025 Annual General Meeting, Addition of Interim Proposals, and Supplementary Meeting Notice
- Announcement on Main Operating Data for Q1 2026
- Announcement on Confirmation of Daily Related Party Transactions in 2025 and Estimated Daily Related Party Transactions in 2026
- Announcement on Conversion Result of Convertible Bonds and Share Changes
- Announcement on Progress in Providing Guarantee Amount for Wholly-owned Subsidiary
Later from Zhejiang Huakang Pharmaceutical
- Announcement on Completing Election of Board of Directors at Expiration of Term of Office, and Appointing Senior Management Members, Head of Audit Department and Securities Affairs Representative
- Indicative Announcement on Signing of the Supplemental Agreement to the Concerted Action Agreement and Change of Controlling Shareholder, Actual Controller, and Equity Interests
- Indicative Announcement on Stopping Conversion of "Huakang Convertible Bonds" when Implementing 2025 Annual Dividend Distribution
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Adjusting the Total Cash Dividends for the 2025 Annual Profit Distribution
Follow Zhejiang Huakang Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Huakang Pharmaceutical